This debate article outlines the arguments favoring a default 12-month duration of dual antiplatelet therapy versus a shorter duration after percutaneous coronary intervention in acute coronary syndrome.
Does a 12-month default duration of dual antiplatelet therapy improve outcomes compared to a shorter duration in acute coronary syndrome patients after percutaneous coronary intervention?
This debate article discusses the pros and cons of a 12-month versus shorter default duration of dual antiplatelet therapy after PCI in ACS patients.
Default duration of dual antiplatelet therapy after percutaneous coronary intervention in acute coronary syndrome patients. The main arguments favouring a 12-month default duration (left) are balanced against those favouring a shorter default duration (right). ACS, acute coronary syndromes; CCS, chronic coronary syndromes; CURE, Clopidogrel in Unstable angina to prevent Recurrent Events; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; NSTE, non-ST-elevation; PCI, percutaneous coronary intervention; PLATO, PLAtelet inhibiTion and patient Outcomes; SAPT, single antiplatelet therapy; STEMI, ST-elevation myocardial infarction; TRITON, TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet iNhibition with prasugrel. Central image modified from https://www.vexels.com/png-svg/preview/298671.
Byrne et al. (2025) conducted an editorial in Acute coronary syndrome after percutaneous coronary intervention. 12-month dual antiplatelet therapy (DAPT) vs. Shorter duration DAPT was evaluated. This debate article outlines the arguments favoring a default 12-month duration of dual antiplatelet therapy versus a shorter duration after percutaneous coronary intervention in acute coronary syndrome.